TiGenix – American Depositary Shares (NASDAQ:TIG) Receives “Buy” Rating from Canaccord Genuity

Canaccord Genuity restated their buy rating on shares of TiGenix – American Depositary Shares (NASDAQ:TIG) in a research report report published on Monday, December 18th. Canaccord Genuity currently has a $50.00 price target on the stock.

Several other research firms have also recently issued reports on TIG. Zacks Investment Research cut TiGenix – American Depositary Shares from a hold rating to a sell rating in a research note on Saturday, October 21st. BidaskClub cut TiGenix – American Depositary Shares from a sell rating to a strong sell rating in a research note on Saturday, December 9th.

TiGenix – American Depositary Shares (NASDAQ TIG) traded up $0.34 during midday trading on Monday, hitting $41.35. The company had a trading volume of 16,798 shares, compared to its average volume of 26,767. The company has a current ratio of 1.37, a quick ratio of 1.36 and a debt-to-equity ratio of 0.10. TiGenix – American Depositary Shares has a 12 month low of $14.30 and a 12 month high of $41.69.

A hedge fund recently bought a new stake in TiGenix – American Depositary Shares stock. EAM Investors LLC acquired a new position in TiGenix – American Depositary Shares (NASDAQ:TIG) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 155,886 shares of the company’s stock, valued at approximately $3,517,000. EAM Investors LLC owned 1.20% of TiGenix – American Depositary Shares at the end of the most recent reporting period. 5.31% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “TiGenix – American Depositary Shares (NASDAQ:TIG) Receives “Buy” Rating from Canaccord Genuity” was published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at https://stocknewstimes.com/2018/01/12/tigenix-tig-earns-buy-rating-from-canaccord-genuity.html.

About TiGenix – American Depositary Shares

TiGenix NV, a biopharmaceutical company, develops and commercializes therapeutics from its proprietary technology platforms of allogeneic or donor derived stem cells. Its stem cell programs are based on proprietary validated platforms of allogeneic expanded stem cells targeting autoimmune, inflammatory, and heart diseases.

Receive News & Ratings for TiGenix - American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TiGenix - American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply